Vice-chairman
Olafur Gudmundsson, born in 1969, is currently the Head of Discovery
Pharmaceutics and Analytical Sciences at Bristol-Myers Squibb (BMS),
a global biopharmaceutical company.
For more than two decades, Gudmundsson has held roles of
increasing responsibility within research and development, covering
multiple therapeutic areas and stages of drug discovery, both for
Bristol-Myers Squibb and Genentech. At BMS, Gudmundsson has
helped bring multiple drug candidates to clinical trials, several of
which have become marketed products.
In his time within the pharmaceutical industry, Gudmundsson’s
responsibilities have included involvement with global portfolio
strategy, evaluation of external acquisitions, strategic innovations, and
integration of merged companies. He has participated in governance
teams providing input on global portfolio optimization and
prioritization, led process optimization teams and chaired integration
teams.
Gudmundsson is also associated with the graduate program of the
Pharmaceutical Chemistry department at Purdue University. Currently,
Gudmundsson is a board member of Eyrir Invest and Noruz.
Gudmundsson has no conflict of interest links with the company’s
main customers. He is a member of the Board of Directors of Eyrir
Invest, Marel’s largest shareholder.
Education
- PhD, Pharmaceutical Chemistry, University of Kansas
- Cand. pharm., Pharmacy, University of Iceland
Board of directors
- Vice-Chairman since 2021
- Board Director since 2014
Sub-committees
- Remuneration Committee
- Nomination Committee
Holdings in Marel
- 1,705,427 shares (as of 30 August 2022)
